We are looking at a three-year span where we may lose over $1 billion. There was no shortage of reasons for the financial pain this past year
While there is no average timeline for these types of cases, negotiating and accepting a settlement may expedite the resolution of the case
Global demand for GLP-1based therapies has expanded rapidly, contributing to supply chain strain, payer scrutiny, and policy debate regarding eligibility and cost containment
Tr li: Hiu qu ca Glutathione 600 c th gim i nu bn ngng s dng, c bit nu khng duy tr ch chm sc da v li sng lnh mnh
It negatively impacts the activity of ribulose-1,5-bisphosphate carboxylase/oxygenase (RuBisCO), CO 2 intake, and the oxygen-evolving complex (Watanabe et al., 2023)